The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

# OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per 4.00 response:

1. Issuer's Identity

1, 100aci o facility				
CIK (Filer ID Nu	mber) Previous Names	X None	Entity Type	
<u>0001671858</u>			X Corporation	
Name of Issue	er		Limited Partnership	
Silverback Therapeutics, In	с.		Limited Liability Company	
Jurisdiction o			General Partnership	
Incorporation/Orga	nization		Business Trust	
DELAWARE			Other (Specify)	
Year of Incorpora	tion/Organization			
Over Five Years Ago				
X Within Last Five Years ( Yet to Be Formed	Specify Year) 2016			
2. Principal Place of Busines	ss and Contact Information	I		
Name	of Issuer			
Silverback Therapeutics, In	с.			
Street A	Address 1		Street Address 2	
500 FAIRVIEW AVENUE	NORTH, SUITE 600			
City	State/Province/Count	ry ZIP/Posta	lCode Phone Number of Issuer	
SEATTLE	WASHINGTON	98109	206-456-2900	
3. Related Persons				
Last Name	Fi	rst Name	Middle Name	
Thompson	Peter			
Street Address 1	Stree	et Address 2		
500 Fairview Ave N #600				
City	State/Pr	ovince/Country	ZIP/PostalCode	
Seattle	WASHINGTO	N	98109	
<b>Relationship:</b> X Executive	Officer X Director Pron	noter		
Clarification of Response (if	f Necessary):			
Last Name	Fi	rst Name	Middle Name	
Hershberg	Robert			
Street Address 1	Stree	et Address 2		
500 Fairview Ave N #600				
City	State/Pr	ovince/Country	ZIP/PostalCode	
Seattle	WASHINGTO	N	98109	
<b>Relationship:</b> Executive	Officer X Director Prom	oter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Islam	Saqib	
<b>Street Address 1</b> 500 Fairview Ave N #600	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	98109
<b>Relationship:</b> Executive Officer X	Director Promoter	
Clarification of Response (if Necessar	ry):	
Last Name	First Name	Middle Name
Root	Jonathan	
<b>Street Address 1</b> 500 Fairview Ave N #600	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	98109
<b>Relationship:</b> Executive Officer X	Director Promoter	
Clarification of Response (if Necessar	ry):	
Last Name	First Name	Middle Name
Schroeder	Thilo	
Street Address 1	Street Address 2	
500 Fairview Ave N #600		
<b>City</b> Seattle	State/Province/Country WASHINGTON	ZIP/PostalCode 98109
<b>Relationship:</b> Executive Officer X		30103
Clarification of Response (if Necessar 4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing	Pharmaceuticals	Telecommunications
Investment Banking Pooled Investment Fund	Other Health Care	
Is the issuer registered as		Other Technology Travel
an investment company under	Manufacturing Real Estate	Airlines & Airports
the Investment Company	Commercial	-
Act of 1940? Yes No	Construction	Lodging & Conventions
Other Banking & Financial Serv		Tourism & Travel Services
Business Services	Residential	Other Travel
Energy		Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		

### 5. Issuer Size

OR	Aggregate Net Asset Value Range
	No Aggregate Net Asset Value
	\$1 - \$5,000,000
	\$5,000,001 - \$25,000,000
	\$25,000,001 - \$50,000,000
	\$50,000,001 - \$100,000,000
	Over \$100,000,000
	Decline to Disclose
	Not Applicable
	OR

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

## 7. Type of Filing

- X New Notice Date of First Sale 2020-03-04 First Sale Yet to Occur Amendment
- 8. Duration of Offering

Does the Issuer intend this offering to last more than one year? X Yes No

9. Type(s) of Securities Offered (select all that apply)

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient

(Associated) Broker or Dealer X None

Recipient CRD Number X None

(Associated) Broker or Dealer CRD Number

<b>Street Address 1</b>	
-------------------------	--

### Street Address 2

State/Province/Country

Foreign/non-US

ZIP/Postal
Code

State(s) of Solicitation (select all that apply)AllCheck "All States" or check individualStates

13. Offering and Sales Amounts

Total Offering Amount	\$78,697,259 USD or	Indefinite
Total Amount Sold	\$31,754,277 USD	
Total Remaining to be Sold	\$46,942,982 USD or	Indefinite

Clarification of Response (if Necessary):

## 14. Investors

City

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:



15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

## \$0 USD X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Silverback Therapeutics, Inc.	Jill E. Fishbein	Jill E. Fishbein	Secretary	2020-03-19

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.